Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Affymax Considers Bankruptcy As Omontys Investigation Continues

This article was originally published in The Pink Sheet Daily

Executive Summary

Affymax cuts staff in order to conserve the little cash it has left in its coffers, which will be needed to pay down debts and continue looking into safety issues surrounding its sole commercial product – an investigation that may never be concluded because the company lacks resources.

You may also be interested in...

When Opportunity Knocks: Eisai Turns To Business Development

Starting in 2006, Eisai embarked on a bold campaign to reorient the company around cancer – with an emphasis on externally sourced innovation – that put aggressive business development front and center. Now as Eisai prepares to launch what may be its most transformative in-licensed product, the weight-loss therapy Belviq, signs of trouble have appeared in its trophy cancer franchise.

Affymax Once-Monthly ESA Will Target Smaller Dialysis Centers

Omontys (peginesatide) launches for chronic kidney disease patients on dialysis, while non-dialysis patients were not included in the labeling due to CV event risk. Pricing negotiations will commence following the March 27 approval.

Amgen To Acquire Panitumumab Development Partner Abgenix

The companies plan to submit a BLA for colorectal cancer agent panitumumab later this week.


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts